Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a commercial-stage medical device company focused on developing bioelectronic therapies for high-burden cardiovascular conditions, including hypertension. The company entered public markets through its merger with Health Assurance Acquisition Corp, a healthcare-sector blank-check vehicle that completed its IPO in 2020 and was sponsored by Health Assurance Capital, LLC. Orchestra BioMed filed its quarterly Form 10-Q with the SEC on May 12, 2026, continuing to report as a fully traded public company more than three years after closing its de-SPAC transaction. Sign up on SpacDesk for full filing data, deal timelines, and ongoing coverage of OBIO and the broader de-SPAC universe.